Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary CES 2017: NeuroMetrix Brings Life-Enhancing Technology to Those Suffering from Chronic Pain
Company unveils advanced product features for Quell Wearable Pain Relief Technology at CES 2017, booth #43421 LAS VEGAS --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq:NURO, NUROW) today announced plans to unveil important advances to its Quell® Wearable Pain Relief Technology™ at CES 2017 (CES
View HTML
Toggle Summary Consumer and Industry Interest High for NeuroMetrix Quell™ Wearable Pain Relief Technology
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) reported strong interest in Quell coming out of last week's Consumer Electronics Show (CES). According to Frank McGillin , SVP and General Manager of Consumer Health at NeuroMetrix , "In the first several days that the
View HTML
Toggle Summary FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain
Key Step Towards Entering Consumer Healthcare Market WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its wearable technology for treatment of chronic pain received 510(k) clearance (K140333) from the U.S. Food and Drug Administration (FDA) for
View HTML
Toggle Summary Jiro Nakamura M.D., Ph.D. Joins NeuroMetrix Scientific Advisory Board
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Jiro Nakamura , M.D., Ph.D., has joined its Scientific Advisory Board . Dr.
View HTML
Toggle Summary Kenneth J. Snow, M.D., Chief Medical Officer of NeuroMetrix, Inc. Interviewed by KIDELA TV
Comments on Early Detection of Diabetes-Related Nerve Disease
View HTML
Toggle Summary NeuroMetrix and GlaxoSmithKline Consumer Healthcare Announce Strategic Collaboration to Develop and Expand Access to Quell Wearable Pain Relief Technology
WALTHAM, Mass. , Jan. 17, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix , Inc. (Nasdaq:NURO) announced today a collaboration with GlaxoSmithKline (NYSE:GSK), one of the world's largest science-led global healthcare companies, involving Quell ®  Wearable Pain Relief Technology™.
View HTML
Toggle Summary NeuroMetrix and SENSUS Pain Management System Spotlighted In Media Outlets and Patient Interviews
WALTHAM, Mass --(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), an innovative health care company that develops wearable medical technology and point-of-care tests to help patients and physicians manage chronic pain, nerve diseases, and sleep disorders, has been featured in several media
View HTML
Toggle Summary NeuroMetrix and SENSUS Pain Management System Spotlighted in Several Media Outlets
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (the "Company") (Nasdaq: NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, has been featured in several media outlets that spotlighted the Company and the SENSUS ™ Pain
View HTML
Toggle Summary NeuroMetrix Announces $13.8 Million At The Market Private Placement of Preferred Stock and Warrants
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NASDAQ : NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 13,800 shares of Series C convertible preferred stock at
View HTML
Toggle Summary NeuroMetrix Announces $21.3 Million at the Market Private Placement of Preferred Stock and Warrants
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NASDAQ : NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 21,300 shares of Series C convertible preferred stock at
View HTML